Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Drops By 38.3%

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 153,293 shares, a decrease of 38.3% from the July 15th total of 248,647 shares. Based on an average daily trading volume, of 118,274 shares, the short-interest ratio is presently 1.3 days. Currently, 1.8% of the shares of the company are sold short.

20/20 Biolabs Price Performance

20/20 Biolabs stock opened at $0.55 on Tuesday. The stock has a market capitalization of $6.74 million and a PE ratio of -1.97. The firm has a 50 day simple moving average of $0.57. 20/20 Biolabs has a 12 month low of $0.40 and a 12 month high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its earnings results on Friday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.73 million during the quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on AIDX shares. Weiss Ratings upgraded shares of 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Maxim Group assumed coverage on shares of 20/20 Biolabs in a research note on Monday, May 11th. They set a “buy” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.